Skip to content

Arvinas ARVN Price / book

Price / book at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
3.4×+1.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
4.4×+2.2×
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
2.5×+1.5×
Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
3.3×+2.9×
Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
14.4×+3.5×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
3.1×0.0×

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on the most recent quarter.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's price / book?
Arvinas (ARVN) reported price / book of 1.8× in Q1 2026.
How has Arvinas's price / book changed year-over-year?
Arvinas's price / book increased by 139.6% year-over-year, from 0.7× to 1.8×.
What is the long-term trend for Arvinas's price / book?
Over 5 years (2020 to 2025), Arvinas's price / book has grown at a -24.1% compound annual growth rate (CAGR), from 7× to 1.8×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.